期刊文献+

Radiofrequency induction on sodium/iodide symporter expression of thyroid cancer

射频诱导甲状腺癌钠/磺转运体表达的研究(英文)
下载PDF
导出
摘要 Objective; The aim of this study was to investigate the effects of radiofrequency treatment on sodium/iodide symporter expression of thyroid cancer ceils. Methods: In 29 thyroid cancer patients with low or no expression of soda / iodide symporter, the radio frequency combined 1311 therapy was used, the whole-body scintigraphy and serum Ig were detected before and after the radiofrequency treatment. Results: The whole-body scintigraphy showed that 4 cases (4/29) before radiofrequenc_y treatment had positive iodine uptake, 19 cases (19/29) two weeks after radiofrequency treatment had the positive iodine uptake, 12 cases (12/29) four weeks after radiofrequency treatment had the positive iodine uptake. Four weeks after radiofrequency treatment, 5 cases had increased serum Ig levels, 17 cases had decreased serum Ig levels, 7 cases showed no change. 25 cases (25/29) were effective, 15 cases (15/29) were cured. Conclusion: The radiofrequency induced the non-expressed the sodium/iodide symporter of thyroid cancer cells regain the iodine intake ability, it improved the clinical efficacy of 131I therapy in dedifferentiated thyroid cancer.
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2013年第11期516-520,共5页 中德临床肿瘤学杂志(英文版)
关键词 thyroid carcinoma radiofrequency ablation sodium/iodide symporter 甲状腺癌 转运体 血清免疫球蛋白 体表 感应 蛋白水平
  • 相关文献

参考文献12

  • 1Foujilas C, Marakaki C, Sirmos N. Sodium-iodine symporter in thy?roid, normal and cancer tissues and its relation to nuclear medicine and to gene cloning treatmen. Hell J Nucl Med, 2009,12: 189-193. 被引量:1
  • 2HP Li, OJ Liu, F Dong. Clinical study on radiofrequency combined with 1311 therapy for dedifferentiated thyroid carcinomas. Chinese?German J Clin Oncol, 2011,10: 274-277. 被引量:1
  • 3Sodre AK, Rubio IG, Galrao AL, et a/. Association of low sodium-io?dide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining. J Clin Endocrinol Metab, 2008, 93: 4141-4145. 被引量:1
  • 4Chinese Medical Association. Guideline of clinical technique and op?eration-nuclear medicine part. Beijing: The People Military Medical Publishing Company, 2004.175-181. 被引量:1
  • 5Eisenhauer EA, Therasse P, Bogaerts J, et a/. New response evalua?tion criteria in solid tumours: revised RECIST guideline (version1.1). Eur J Cancer, 2009, 45: 228-247. 被引量:1
  • 6Li W, Ain KB. Human sodium-iodide symporter (hNIS) gene expres?sion is inhibited by a trans-active transcriptional repressor, NIS-re?pressor, containing PARP-1 in thyroid cancer cells. Endocr Relat Cancer, 2010,17: 383-398. 被引量:1
  • 7XF Hou, OJ Liu, SH Ma. Correlation analysis between serum ~2-MG and sodium/iodide symporter in patients with thyroid carcinoma. Chi?nese-German J Clin Oncol, 2013, 12: 65-67. 被引量:1
  • 8Wan DS. Clinical oncology. Beijing: The Scientific Publishing Com?pany (Chinese), 2005.171-179. 被引量:1
  • 9Kim WG, Kim EY, Kim TY, et al. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J, 2009, 56: 105-1012. 被引量:1
  • 10Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging, 2002, 29: 775-782. 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部